Neurodegenerative disorders such as Parkinson's (PD) and Alzheimer's (AD) diseases are a significant and growing concern to the population. During the aging process, abnormal accumulation and misfolding of a-synuclein (SYN) and amyloid-b protein (Ab) in selected neuronal groups leads to a wide spectrum of neurological disorders with cognitive dysfunction, parkinsonism, and autonomic dysfunction. Together, these disorders account for the great majority of the cases with combined movement disorders and dementia in the US. Therefore, better understanding the pathogenesis of these disorders and developing new therapies is a major priority.
Ihara et al. in this issue of Neuron report that Sept4, a novel scaffold protein, is reduced in the caudo-putamen region of patients with PD. Moreover, the authors found that Sept4 plays an important role in facilitating dopaminergic transmission at the synapse terminals of the striato-nigral pathway (Ihara et al., 2007 ) and also appears to have a role in modulating the pathological alterations associated with the accumulation of oligomerized phosphorylated SYN in a transgenic mouse model of PD.
Septin proteins were first isolated in yeast as components of the septin ring responsible for the budding of the daughter cell from the mother cell in cell division. All septins are GTPbinding proteins that appear to act in scaffold functions (Longtine and Bi, 2003) . The family of septins is highly conserved across species as wideranging as worms, flies, mice, and humans. In humans, more than 12 septin genes have been isolated with numerous splice variants, accounting for an even greater variability. Functions of these septins in mammals are quite diverse and include roles in apoptosis, exocytosis, cytokinesis, and microtubule and actin function (reviewed in Hall and Russell [2004] ). Many of these roles rely on septins to provide a scaffold for the correct vesicle trafficking or assembly of signaling complexes (Kartmann and Roth, 2001) .
Scaffold proteins such as spectrins, caveolin, and flotillin have been previously shown to play important roles in synaptic transmission by integrating signaling pathways and regulating the cycling of receptors (Pielage et al., 2005) . These modulatory effects of scaffold molecules on signaling pathways such as ERK, JNK, and Akt might occur at the caveolae (Smart et al., 1999 ; Figure 1 ). These areas of specialized membrane, also known as lipid rafts, are enriched in scaffolding molecules. Alterations in scaffold proteins have been previously observed in AD, PD, and prion diseases (Figure 1) . Moreover, alterations in neuronal signaling in these disorders might be related to the accumulation of misfolded molecules including Huntingtin (Htt), Ab, PrP, and SYN.
Abnormalities in septin expression or function in humans have been linked to numerous diseases. Chromosomal translocations resulting in the fusion of MLL with septin 5, 6, 9, or 11 have been linked with leukemia (Kreuziger et al., 2007) . Additionally, Sept9 has been linked to sporadic ovarian and breast cancer (Russell et al., 2000) . In neuronal diseases, septins 1, 2, and 4 have been found localized at the site of neurofibrillary Tau tangles in AD, although the significance of this has not been determined (Hall and Russell, 2004) . In addition, polymorphisms in Sept3 have been associated with AD (Takehashi et al., 2004) . Furthermore, Sept5 has been reported to bind Parkin and has been shown to accumulate in patients with juvenile parkinsonism. Although numerous septin knockout mice have been generated, only the Sept4 knockout appears to exhibit neuronal abnormalities.
Ihara et al. examined the role of Sept4 in the presynaptic termini scaffold as well as in the pathogenesis of PD. Their study describes three significant findings: (1) in cases with PD, Sept4 colocalizes with SYN and is downregulated in the putamen of these patients; (2) loss of Sept4 in knockout mice resulted in decreased dopamine release, an effect which was recovered when these mice were crossed with a Sept4 transgenic mouse; and (3) Sept4 binds SYN, preventing both its phosphorylation and oligomerization. Interestingly, Sept4 interactswith dopamine transporter (DAT), stx, snap25, and SYN, all proteins that are involved in the dopaminergic system. Additionally, crosses of the Setp4 knockout mouse with the SYN transgenic A53T mouse, a model of PD, exacerbated the neuronal loss and behavioral phenotype. Thus, Sept4 appears to play an innate role in the dopaminergic pathway, possibly by acting as a scaffold for the assembly and release of vesicles and interactions with other synaptic molecules (Figure 1) .
These findings naturally lead us to ask the following question: can Sept4 be utilized as a therapy for PD ? Ihara et al. (2007) described a reduction in the expression of Sept4 in the putamen of patients with PD. This, along with the data showing a relationship between the presence of Sept4 and prevention of oligomerization of SYN, supports the potential value of Sept4 as a therapeutic target. In this context, it may be possible to treat some forms of PD by upregulating the expression of Sept4 at the synapses. Ihara et al. (2007) describe that overexpression of Sept4 is potentially toxic in the mouse; however, this model was a transgenic animal containing Sept4 driven from the prion promoter. The mouse exhibited early death and loss of fertility, indicating that expression of Sept4 above endogenous levels may not be beneficial. It would have been interesting to determine if crossing the Sept4 transgenic with the SYN transgenic would have had an effect on dopaminergic neuronal survival. Moreover, it remains to be clarified why Sept4 expression is reduced in PD.
Another potential therapeutic approach with Sept4 may be localized delivery of the gene to the site of neuronal cell death. Stereotactic delivery of either a lentiviral or AAV vector expressing Sept4 from a dopaminergic neuronal-specific promoter might provide the beneficial effects of preventing SYN aggregation without the detrimental effects of early death observed in the transgenic mouse. We have previously shown that a similar approach using lentiviral vectors expressing other chaperone molecules might be effective at suppressing SYN aggregation and toxicity (Hashimoto et al., 2004; Klucken et al., 2004) . In summary, this study provides new evidence for the role of scaffold molecules such as septins in synaptic transmission and neurodegenerative diseases and uncovered a new pathway for better understanding the pathogenesis of PD and developing new treatments.
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